1. Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New 
Anagha Bangalore Kumar, MBBS, Rachel Maus, PhD, Svetomir N. Markovic, MD, PhD 
Mayo Clinic Proceedings 
Volume 93, Issue 7, Pages (July 2018)
DOI: /j.mayocp
Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
The action of cytotoxic T-lymphocyte–associated protein (CTLA) inhibitors. Ipilimumab is an anti–CTLA-4 antibody that causes blockade of CTLA-4, resulting in prolonged T-cell activation, proliferation, and antitumor response.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Figure 2
The action of anti–programmed cell death 1 (PD-1) and anti–programmed death ligand-1 (PD-L1) blockers.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

4. Figure 3 The concept of adoptive cell therapy.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions